ZA200402500B - Novel dipeptidyl peptidase IV (DP-IV) inhibitors as antidiabetic agents. - Google Patents
Novel dipeptidyl peptidase IV (DP-IV) inhibitors as antidiabetic agents.Info
- Publication number
- ZA200402500B ZA200402500B ZA200402500A ZA200402500A ZA200402500B ZA 200402500 B ZA200402500 B ZA 200402500B ZA 200402500 A ZA200402500 A ZA 200402500A ZA 200402500 A ZA200402500 A ZA 200402500A ZA 200402500 B ZA200402500 B ZA 200402500B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitors
- dipeptidyl peptidase
- antidiabetic agents
- novel dipeptidyl
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0125446.5A GB0125446D0 (en) | 2001-10-23 | 2001-10-23 | Novel anti-diabetic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200402500B true ZA200402500B (en) | 2005-01-24 |
Family
ID=9924376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200402500A ZA200402500B (en) | 2001-10-23 | 2004-03-30 | Novel dipeptidyl peptidase IV (DP-IV) inhibitors as antidiabetic agents. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7144886B2 (xx) |
| EP (1) | EP1450794A1 (xx) |
| JP (1) | JP2005510499A (xx) |
| KR (1) | KR20040049321A (xx) |
| CN (1) | CN1329375C (xx) |
| AR (1) | AR037247A1 (xx) |
| CA (1) | CA2464256A1 (xx) |
| GB (1) | GB0125446D0 (xx) |
| HU (1) | HUP0402403A3 (xx) |
| IL (1) | IL161192A0 (xx) |
| MX (1) | MXPA04003828A (xx) |
| NO (1) | NO20042114L (xx) |
| NZ (1) | NZ532044A (xx) |
| PL (1) | PL370149A1 (xx) |
| RU (1) | RU2004110055A (xx) |
| UY (1) | UY27511A1 (xx) |
| WO (1) | WO2003035067A1 (xx) |
| ZA (1) | ZA200402500B (xx) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| DE60235212D1 (de) | 2001-06-27 | 2010-03-11 | Smithkline Beecham Corp | Fluoropyrrolidine als Dipeptidylpeptidasehemmer |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| DE60223920T2 (de) | 2001-06-27 | 2008-11-13 | Smithkline Beecham Corp. | Pyrrolidine als dipeptidyl-peptidase-inhibitoren |
| ATE462432T1 (de) | 2003-05-05 | 2010-04-15 | Probiodrug Ag | Glutaminylcyclase-hemmer |
| EP1622870A2 (en) * | 2003-05-05 | 2006-02-08 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
| DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| DE10348044A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| EP1675578B9 (en) | 2003-10-15 | 2014-06-25 | Probiodrug AG | Inhibitors of glutaminyl and glutamate cyclases for the treatment of the neurodegenerative diseases fbd and fdd |
| DE10348023A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| NZ546887A (en) | 2003-11-03 | 2009-04-30 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| BRPI0416628A (pt) | 2003-11-17 | 2007-01-16 | Novartis Ag | uso de compostos orgánicos |
| RU2766487C2 (ru) | 2004-01-20 | 2022-03-15 | Новартис Аг | Композиция и способ прямого прессования |
| AU2005210004B2 (en) | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| CA2599419A1 (en) * | 2005-04-22 | 2006-11-02 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-iv inhibitors |
| MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| KR20100114944A (ko) * | 2005-08-11 | 2010-10-26 | 에프. 호프만-라 로슈 아게 | Ｄｐｐ-ｉｖ 억제제를 포함하는 약학 조성물 |
| ME02005B (me) | 2005-09-14 | 2012-08-31 | Takeda Pharmaceuticals Co | Inhibitori dipeptidil peptidaze za lečenje dijabetesa |
| EP1924567B1 (en) | 2005-09-16 | 2012-08-22 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| WO2007120689A2 (en) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
| WO2007116092A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| EP2146210A1 (en) * | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
| EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| EP2545047B9 (en) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
| SG11201707276PA (en) | 2015-03-09 | 2017-10-30 | Intekrin Therapeutics Inc | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959248A (en) * | 1974-04-03 | 1976-05-25 | Merck & Co., Inc. | Analogs of thyrotropin-releasing hormone |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| GB0010183D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
-
2001
- 2001-10-23 GB GBGB0125446.5A patent/GB0125446D0/en not_active Ceased
-
2002
- 2002-10-22 AR ARP020103995A patent/AR037247A1/es unknown
- 2002-10-22 UY UY27511A patent/UY27511A1/es not_active Application Discontinuation
- 2002-10-23 CA CA002464256A patent/CA2464256A1/en not_active Abandoned
- 2002-10-23 EP EP02801961A patent/EP1450794A1/en not_active Withdrawn
- 2002-10-23 PL PL02370149A patent/PL370149A1/xx not_active Application Discontinuation
- 2002-10-23 CN CNB028208544A patent/CN1329375C/zh not_active Expired - Fee Related
- 2002-10-23 RU RU2004110055/04A patent/RU2004110055A/ru not_active Application Discontinuation
- 2002-10-23 JP JP2003537634A patent/JP2005510499A/ja not_active Withdrawn
- 2002-10-23 US US10/491,288 patent/US7144886B2/en not_active Expired - Fee Related
- 2002-10-23 WO PCT/GB2002/004787 patent/WO2003035067A1/en not_active Application Discontinuation
- 2002-10-23 NZ NZ532044A patent/NZ532044A/en unknown
- 2002-10-23 HU HU0402403A patent/HUP0402403A3/hu unknown
- 2002-10-23 KR KR10-2004-7005917A patent/KR20040049321A/ko not_active Application Discontinuation
- 2002-10-23 IL IL16119202A patent/IL161192A0/xx unknown
- 2002-10-23 MX MXPA04003828A patent/MXPA04003828A/es active IP Right Grant
-
2004
- 2004-03-30 ZA ZA200402500A patent/ZA200402500B/xx unknown
- 2004-05-19 NO NO20042114A patent/NO20042114L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2004110055A (ru) | 2005-10-20 |
| JP2005510499A (ja) | 2005-04-21 |
| CN1575171A (zh) | 2005-02-02 |
| EP1450794A1 (en) | 2004-09-01 |
| US7144886B2 (en) | 2006-12-05 |
| HUP0402403A2 (hu) | 2005-04-28 |
| US20050004205A1 (en) | 2005-01-06 |
| NZ532044A (en) | 2005-03-24 |
| IL161192A0 (en) | 2004-08-31 |
| AR037247A1 (es) | 2004-11-03 |
| CA2464256A1 (en) | 2003-05-01 |
| GB0125446D0 (en) | 2001-12-12 |
| PL370149A1 (en) | 2005-05-16 |
| WO2003035067A1 (en) | 2003-05-01 |
| NO20042114L (no) | 2004-07-21 |
| HUP0402403A3 (en) | 2009-05-28 |
| UY27511A1 (es) | 2003-04-30 |
| CN1329375C (zh) | 2007-08-01 |
| KR20040049321A (ko) | 2004-06-11 |
| MXPA04003828A (es) | 2004-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200402500B (en) | Novel dipeptidyl peptidase IV (DP-IV) inhibitors as antidiabetic agents. | |
| EP1465891A4 (en) | INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | |
| MXPA03000966A (es) | Agentes antidiabeticos. | |
| AU2003207881A1 (en) | Dipeptidyl peptidase inhibitors | |
| EE200200604A (et) | Dipeptidüüli peptidaasi IV inhibiitorid | |
| EP1997533B8 (en) | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | |
| IL161158A0 (en) | N - substituted pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors | |
| ZA200402501B (en) | Inhibitors of post-proline cleaving proteases. | |
| WO2002002560A3 (en) | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) | |
| TW200634018A (en) | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses | |
| ATE455759T1 (de) | Fluoropyrrolidine als dipeptidylpeptidasehemmer | |
| HK1049330B (zh) | 二肽肽酶iv的稠合6-環丙基的以吡咯烷為本的抑制物及方法 | |
| AU2003286776A1 (en) | Novel inhibitors of dipeptidyl peptidase iv | |
| WO2006071762A3 (en) | Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods | |
| IL159152A0 (en) | 3-fluoro-pyrrolidines as antidiabetic agents | |
| WO2003000181A3 (en) | Dipeptidyl peptidase inhibitors for the treatment of diabetes | |
| EP1406872A4 (en) | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | |
| IL188471A0 (en) | Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus | |
| DE602004010206D1 (de) | Dipeptidyl Peptidase Inhibitoren. | |
| MXPA03008356A (es) | Compuestos del tipo no imidazol como antagonistas de histamina h3. | |
| AU2002316437A1 (en) | Pyrrolidines as dipeptidyl peptidase inhibitors | |
| MXPA03009558A (es) | Compuestos novedosos. | |
| MXPA03007310A (es) | Derivados de ftalazinona piperidino como inhibidores pde4. | |
| MXPA03004534A (es) | Compuestos novedosos para su uso como inhibidores de la proteasa del virus de inmunodeficiencia humana (vih). | |
| AU2003287325A8 (en) | N-cycloalkylglycines as hiv protease inhibitors |